Overview
| Product name | Recombinant Human TNFRSF4/OX40/CD134 Protein |
|---|
| Catalog No. | RP01357 |
|---|
| Description | Recombinant Human TNFRSF4/OX40/CD134 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Leu29-Ala216) of human OX40/TNFRSF4/CD134 (Accession #NP_003318.1) fused with a 6×His tag at the C-terminus. |
|---|
| Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized Human OX40 at 2 μg/mL (100 μL/well) can bind Human OX40 Ligand/TNFSF4 Protein with a linear range of 156.25-872.87 ng/mL.
|
|---|
| Purity | > 90% by SDS-PAGE. |
|---|
| Endotoxin | Please contact us for more information. |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
|---|
| Species | Human |
|---|
| Calculated MW | 21.00 kDa |
|---|
Background
OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.
Product information
| Synonym | TNFRSF4; ACT35; CD134; IMD16; OX40; TXGP1L |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
